WallStSmart

MercadoLibre Inc. (MELI)vsNovo Nordisk A/S (NVO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novo Nordisk A/S generates 1035% more annual revenue ($327.80B vs $28.89B). NVO leads profitability with a 37.2% profit margin vs 6.9%. MELI appears more attractively valued with a PEG of 1.14. NVO earns a higher WallStSmart Score of 74/100 (B).

MELI

Buy

60

out of 100

Grade: C+

Growth: 7.3Profit: 6.5Value: 6.7Quality: 5.3
Piotroski: 2/9Altman Z: 2.04

NVO

Strong Buy

74

out of 100

Grade: B

Growth: 9.3Profit: 10.0Value: 5.7Quality: 4.8
Piotroski: 3/9Altman Z: 2.13
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MELIUndervalued (+59.2%)

Margin of Safety

+59.2%

Fair Value

$4942.58

Current Price

$1632.52

$3310.06 discount

UndervaluedFair: $4942.58Overvalued

Intrinsic value data unavailable for NVO.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MELI4 strengths · Avg: 9.3/10
Return on EquityProfitability
36.0%10/10

Every $100 of equity generates 36 in profit

Revenue GrowthGrowth
44.6%10/10

Revenue surging 44.6% year-over-year

Market CapQuality
$94.80B9/10

Large-cap with strong market position

Free Cash FlowQuality
$2.08B8/10

Generating 2.1B in free cash flow

NVO6 strengths · Avg: 10.0/10
Market CapQuality
$202.85B10/10

Mega-cap, among the largest globally

P/E RatioValuation
10.6x10/10

Attractively priced relative to earnings

Return on EquityProfitability
71.4%10/10

Every $100 of equity generates 71 in profit

Profit MarginProfitability
37.2%10/10

Keeps 37 of every $100 in revenue as profit

Operating MarginProfitability
61.6%10/10

Strong operational efficiency at 61.6%

EPS GrowthGrowth
67.1%10/10

Earnings expanding 67.1% YoY

Areas to Watch

MELI4 concerns · Avg: 3.0/10
Price/BookValuation
12.3x4/10

Trading at 12.3x book value

Profit MarginProfitability
6.9%3/10

6.9% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
47.4x2/10

Premium valuation, high expectations priced in

NVO2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
4.882/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : MELI

The strongest argument for MELI centers on Return on Equity, Revenue Growth, Market Cap. Revenue growth of 44.6% demonstrates continued momentum. PEG of 1.14 suggests the stock is reasonably priced for its growth.

Bull Case : NVO

The strongest argument for NVO centers on Market Cap, P/E Ratio, Return on Equity. Profitability is solid with margins at 37.2% and operating margin at 61.6%. Revenue growth of 24.0% demonstrates continued momentum.

Bear Case : MELI

The primary concerns for MELI are Price/Book, Profit Margin, Piotroski F-Score. A P/E of 47.4x leaves little room for execution misses.

Bear Case : NVO

The primary concerns for NVO are Piotroski F-Score, PEG Ratio.

Key Dynamics to Monitor

MELI profiles as a hypergrowth stock while NVO is a growth play — different risk/reward profiles.

MELI carries more volatility with a beta of 1.41 — expect wider price swings.

MELI is growing revenue faster at 44.6% — sustainability is the question.

NVO generates stronger free cash flow (12.0B), providing more financial flexibility.

Bottom Line

NVO scores higher overall (74/100 vs 60/100), backed by strong 37.2% margins and 24.0% revenue growth. MELI offers better value entry with a 59.2% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

MercadoLibre Inc.

CONSUMER CYCLICAL · INTERNET RETAIL · USA

MercadoLibre, Inc. operates online trading platforms in Latin America. The company is headquartered in Buenos Aires, Argentina.

Novo Nordisk A/S

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.

Want to dig deeper into these stocks?